Integrated Platform for Brain Imaging and Drug Delivery Across the Blood–Brain Barrier

Methods in Molecular Biology

Volumn 686, Issue , 2011, Pages 465-481

  Iqbal, Umar ^a   Abulrob, Abedelnasser ^a   Stanimirovic, Danica B ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Blood brain barrier; Doxorubicin; Drug delivery; FC5; Imaging agent; In vivo time domain optical imaging; Liposome; Single domain antibodies

Indexed keywords

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DOXORUBICIN; LIPOSOME; NANOPARTICLE;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MAPPING; BRAIN TUMOR; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; MOUSE; SYNTHESIS; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN MAPPING; BRAIN NEOPLASMS; CONTRAST MEDIA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; LIPOSOMES; MICE; NANOPARTICLES;

MLCS; MLOWN;

EID: 79957680089     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-938-3_24     Document Type: Chapter

References (31)

1. Pardridge, W. M., Buciak, J. L., and Friden, P.M. (1991) Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo J Pharmacol Exp Ther 259, 66–70.
2. Coloma, M. J., Lee, H. J., Kurihara, A., Landaw, E. M., Boado, R.J., Morrison, S. L., and Pardridge, W. M. (2000) Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor Pharm Res 17, 266–74.
3. Gaillard, P. J., Visser, C.C., and de Boer, A. G. (2005) Targeted delivery across the blood-brain barrier Expert Opin Drug Deliv 2, 299–309.
4. Demeule, M., Regina, A., Jodoin, J., Laplante, A., Dagenais, C., Berthelet, F., Moghrabi, A., and Beliveau, R. (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier Vascul Pharmacol 38, 339–48.
5. Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E., and Strickland, D. K. (2008) LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies Physiol Rev 88, 887–918.
6. Abulrob, A., Sprong, H., Van Bergen en Henegouwen, P., and Stanimirovic, D. (2005) The blood-brain barrier transmigrating single domain antibodies: mechanisms of transport and antigenic epitopes in human brain endothelial cells J Neurochem 95, 1201–14.
7. Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E. B., Bendahman, N., and Hamers, R. (1993) Naturally occurring antibodies devoid of light chains Nature 363, 446–8.
8. Holliger, P. and Hudson, P. J. (2005) Engineered antibody fragments and the rise of single domains Nature Biotechnology 23, 1126–36.
9. Muyldermans, S. (2001) Single domain camel antibodies: current status J Biotechnol 74, 277–302.
10. Muruganandam, A., Tanha, J., Narang, S., and Stanimirovic, D. (2002) Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium FASEB J 16, 240– 2.
11. Tanha, J., Muruganandam, A., and Stanimirovic, D. (2003) Phage display technology for identifying specific antigens on brain endothelial cells Methods Mol Med 89, 435–49.
12. Torchilin, V. P. (2005) Recent advances with liposomes as pharmaceutical carriers Nat Rev Drug Discov 4, 145–60.
13. Boado, R. J. (2007) Blood-brain barrier transport of non-viral gene and RNAi therapeutics Pharm Res 24, 1772–87.
14. Summerfield, S. G., Lucas, A.J., Porter, R. A., Jeffrey, P., Gunn, R. N., Read, K. R., Stevens, A. J., Metcalf, A. C., Osuna, M. C., Kilford, P. J., Passchier, J., and Ruffo, A. D. (2008) Toward an improved prediction of human in vivo brain penetration Xenobiotica 38, 1518–35.
15. Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., and Allen, T. M. (1995) Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures Biochim Biophys Acta 1239, 133–44.
16. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., and Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51, 691–743.
17. Bowman, P. D., Ennis, S. R., Rarey, K. E., Betz, A. L., and Goldstein, G. W. (1983) Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability Am Neurol 14, 396–402.
18. Charrois, G. J. and Allen, T. M. (2003) Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity J Pharmacol Exp Ther 306, 1058–67.
19. Richter, W. S. (2006) Imaging biomarkers as surrogate endpoints for drug development Eur J Nucl Med Mol Imaging 33 Suppl 1, 6–10.
20. Cheng, W. W. and Allen, T. M. (2008) Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv J Control Release 126, 50–8.
21. Zhou, Y., Drummond, D. C., Zou, H., Hayes, M. E., Adams, G. P., Kirpotin, D. B., and Marks, J. D. (2007) Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells J Mol Biol 371, 934–47.
22. Abulrob, A., Zhang, J., Tanha, J., Mackenzie, R. and Stanimirovic, D. (2005b) Single domain antibodies: blood brain barrier delivery vectors. Theme “Drug Transport(ers) & Diseased Brain” International Congress Series 1277, 212–23.
23. Takamiya, Y., Abe, Y., Tanaka, Y., Tsugu, A., and Kazuno, M. (1997) Murine P-glycoprotein on stromal vessels mediates multidrug resistance in intracerebral human glioma xeno-grafts Br J Cancer 76, 445–50.
24. Frangioni, J. V. (2003) In vivo near-infrared fluorescence imaging Curr Opin Chem Biol 7, 626–34.
25. Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies Clin Pharmacokinet 42, 419–36.
26. Ryan, S. M., Mantovani, G., Wang, X., Haddleton, D. M., and Brayden, D. J. (2008) Advances in PEGylation of important biotech molecules: delivery aspects Expert Opin Drug Deliv 5, 371–83.
27. Caruthers, S. D., Winter, P. M., Wickline, S. A., and Lanza, G. M. (2006) Targeted magnetic resonance imaging contrast agents Methods Mol Med 124, 387–400.
28. Kulkarni, S. B., Betageri, G. V., and Singh, M. (1995) Factors affecting microencapsulation of drugs in liposomes J Microencapsul 12, 229–46.
29. Kepczyński, M., Nawalany, K., Kumorek, M., Kobierska, A., Jachimska, B., and Nowakowska, M. (2008) Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem Phys Lipids 155, 7–15.
30. Chikh, G. G., Li, W. M., Schutze-Redelmeier, M. P., Meunier, J. C., and Bally, M. B. (2002) Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal ion chelating lipids Biochem Biophys Acta 1567, 204–12.
31. Emanuel, N., Eli, K., Bolotin, E. M., Smorodinsky, N. I., and Barenholz, Y. (1996) Preparation and characterization of doxorubi-cin-loaded sterically stabilized immunolipo-somes Pharmaceutical Res 3, 352–9.